Clinical trials: Advance Lung Cancer
Non-Small Cell Lung Cancer, Carcinoma
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
Study comparing two regimens of nab-paclitaxel and carboplatin combination in elderly subjects (≥ 70 years old) with advanced NSCLC
- Conditions
- Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma
- Trial name
- ABOUND 70+ (NCT02151149)
- Testing
- nab-paclitaxel, Carboplatin
- Where
- 55 sites in United States
- Volunteers
- 143 people
- Sponsor
- Celgene
Non-small Cell Lung Cancer
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
The purpose of this is to evaluate the efficacy and safety of imetelstat (GRN163L) as maintenance therapy for patients with advanced stage NSCLC who have not progressed after 4 cycles of platinum based therapy.
- Trial name
- NCT01137968
- Testing
- imetelstat, Bevacizumab
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 116 people
- Sponsor
- Geron Corporation
Critical Illness, Chronic Obstructive Lung Disease
Advance Care Planning Evaluation in Hospitalized Elderly Patients
The purpose of the study is to inform decision-makers of the best strategies to implement advanced care planning (ACP). An advanced care plan (ACP) is a verbal or written instruction describing what kind of care an individual…
- Conditions
- Critical Illness, Chronic Obstructive Lung Disease, Congestive Heart Failure, Cirrhosis
- Trial name
- ACCEPT (NCT01362855)
- Where
- 9 sites in Canada
- Volunteers
- 503 people, healthy volunteers welcome
- Sponsor
- Daren K. Heyland
Early Detection of Cancer, Telemedicine
Integrating Telehealth to Advance Lung Cancer Screening
The goal of this pragmatic trial is to learn if telehealth strategies can increase shared decision-making (SDM) for lung cancer screening (LCS).
- Conditions
- Early Detection of Cancer, Telemedicine, Decision Making
- Trial name
- ITALCS (NCT06638554)
- Testing
- Active Choice, Telehealth Only, Low Touch Strategy
- Where
- United States
- Volunteers
- 6,000 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Advanced Lung Non-Small Cell Carcinoma, Non-Small Cell Carcinoma of Lung, TNM Stage 4
A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Metastatic lung cancer is the leading cause of cancer mortality worldwide with a 5-year survival of less than 5%. With the approval of programmed cell death 1 (PD-1) inhibitors in advanced lung cancer, such as pembrolizumab…
- Trial name
- NCT04856176
- Testing
- Granulocyte-Macrophage Colony-Stimulating Factor, Pembrolizumab, pemetrexed
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Tufts Medical Center
Congestive Heart Failure, Cancer
Team-based Versus Primary Care Clinician-led Advance Care Planning in Practice-based Research Networks
This project compares two models of the Serious Illness Care Program (SICP) in primary care: clinician-focused SICP and team-based SICP.
- Conditions
- Congestive Heart Failure, Cancer, Chronic Obstructive Pulmonary Disease, Cerebrovascular Accident
- Trial name
- NCT03577002
- Testing
- Serious Illness Care Program (SICP)
- Where
- 7 sites in United States, Canada
- Volunteers
- 1,120 people
- Sponsor
- Oregon Health and Science University
Adenocarcinoma, Non-small Cell Lung Cancer
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
The purpose of this trial is to figure out what effects (good or bad) the investigational drug agent called Tarceva (erlotinib; OSI-774) has on women with previously untreated adenocarcinoma.
- Trial name
- NCT00137839
- Testing
- Erlotinib
- Where
- 3 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pasi A. Janne, MD, PhD
Advanced Solid Tumor, Advanced or Metastatic Non-small Cell Lung Cancer
Phase I Study of the BBP-398 in Patients With Advance Solid Tumors
This is an open label, dose escalation and expansion, two-part Phase I study for SHP-2 inhibitor BBP-398 to evaluate the safety, tolerability, pharmacokinetics, determine MTD and/or RP2D, and preliminary anti- cancer activity in…
- Trial name
- NCT05621525
- Testing
- BBP-398
- Where
- 2 sites in China
- Volunteers
- 7 people
- Sponsor
- LianBio LLC
Ovarian, Melanoma
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid…
- Conditions
- Ovarian, Melanoma, Renal, Prostate
- Trial name
- NCT00423254
- Testing
- PSMA/PRAME
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mannkind Corporation
Non-small Cell Lung Carcinoma
Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC)
The aim of the study is to assess current practice within PROP \& lung teams, for treating asymptomatic patients with centrally located non-small cell lung cancer (NSCLC), and to observe outcomes for those patients receiving…
- Trial name
- NCT01279408
- Testing
- None: Questionnaire Study
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- University Health Network, Toronto